Bavarian Nordic A/S · OMXCOP:BAVA

Bavarian Nordic A/S — Q3 2026 Earnings Presentation

20 slides from Bavarian Nordic A/S's earnings presentation, Nov 13, 2026

  1. Slide 1: Bavarian Nordic Q3 2026 Results Conference Call

    Bavarian Nordic Q3 2026 Results Conference Call November 13, 2026

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-lo

  3. Slide 3: Agenda

    Agenda • Key highlights • Travel Health Tarja Stenvall CEO • Public Preparedness • Pipeline • Commercial performance • Financials Henrik Juuel CFO • Outlook 2026 • Q&A 3

  4. Slide 4: Tarja Stenvall, CEO

    Tarja Stenvall, CEO 4

  5. Slide 5: Strong momentum for Bavarian Nordic's next chapter

    Strong momentum for Bavarian Nordic’s next chapter • Solid performance in 9M 2026, driven by continued growth in Travel Health and solid execution in Public Preparedness • Strong foundation for the future, with a growing global Travel Health business and an established position as a trusted partner

  6. Slide 6: Strong commercial performance in 9M

    Strong commercial Key highlights 9M 2026 performance in 9M Travel Health growth of 24%¹ in 9M 2026 (22% in Q3 2026), driven by continued rabies momentum, supported by continued launch of chikungunya Revenue EBITDA margin vaccine Public Preparedness 4,897 mDKK 34.9% in line with expectations, still a

  7. Slide 7: Henrik Juuel, CFO

    Henrik Juuel, CFO 7

  8. Slide 8: Another strong quarter for Travel Health

    Another strong quarter for Travel Health, Q3/9M 2026 revenue Travel Health +24%* 2,886 +22%* 2,327 Rabies TBE 941 1,144 mDKK • Continued strong growth in Q3 driven by • After strong performance in Q2, Q3 was market growth and strong execution impacted by supply constraints driving Q3 2025 Q3 2026 9M

  9. Slide 9: Rabies in the US: increased awareness driving market growth

    Rabies in the US: human-animal encounters leading to increased awareness driving market growth Strong >30% rabies market growth in the US driven by: +17% Rabies related US CDC inquiries, July-August 2026 vs July-August 2025¹ Exposure risk increasing with outdoor activity ‘Rabies’ search interest on

  10. Slide 10: Continued launch of Vimkunya

    Continued launch of Chikungunya, Vimkunya Q3/9M 2026 revenue +258% 151 • Strong performance in several European markets • US uptake remained slower due to conservative interpretation of the +146% recommendation and pending MMWR publication 73 42 30 Regulatory and launch status mDKK • Approved in the

  11. Slide 11: Public Preparedness in line with expectations

    Public Preparedness in line with Public Preparedness, Q3/9M 2026 revenue expectations 2,334 -20% -23% 1,875 Public Preparedness orders Ongoing studies 788 606 mDKK • Q3 revenue in line with expectations • Phase 4: Post-exposure vaccination with MVA-BN being • 2026 revenue not materially impacted by

  12. Slide 12: Vaccines for global mpox emergency stockpile

    Vaccines for global mpox emergency stockpile Donation of 75,000 MVA-BN doses to new global mpox vaccine emergency stockpile The donation complements a newly awarded contract to supply 150,000 doses to the stockpile Building emergency reserves in global mpox preparedness helps ensure timely and equit

  13. Slide 13: Supporting long-term public preparedness in the UK

    Supporting long-term public preparedness in the UK • A new multi-year contract awarded by the UK government through the UK Health Security Agency (UKHSA) for supply of MVA-BN • The contract supports long-term preparedness against emerging infectious disease threats in the UK • A four-year contract u

  14. Slide 14: Pipeline progress

    Pipeline progress Pipeline Post-approval Phase 1 Phase 2 Phase 3 commitments Increased regulatory obligations and continuous focus on Chikungunya product enhancement to stay competitive, including post-approval commitments for chikungunya vaccine MVA-BN cell line Ongoing MVA-BN cell line being devel

  15. Slide 15: Commercial performance

    Commercial performance • Total reported revenue growth of 0.6% in Q3 impacted by FX and discontinued business of 6.8% leading to organic growth of 7.4% • Strong Travel Health performance in both mDKK Q3 2026 Q3 2025 Growth 9M 2026 9M 2025 Growth Q3 (+21.6%) and 9M (+24.1%) Public Preparedness JYNNEO

  16. Slide 16: Financials

    Financials mDKK Q3 2026 Q3 2025 9M 2026 9M 2025 • Q3 gross margin increased 2.1%-points Revenue 1,805 1,795 4,897 4,793 y-o-y driven by beneficial Production costs 868 902 2,255 2,306 product/country mix Gross profit 937 893 2,642 2,487 • R&D costs mainly driven by Vimkunya Gross margin 51.9% 49.8%

  17. Slide 17: Cash flow

    Cash flow • Positive cash flow from operating activities in 9M following Cash flow positive net profit being partly offset by increased working capital Q3 Q3 9M 9M mDKK • Negative impact from working capital primarily 2026 2025 2026 2025 following high receivable position and reduction in Cash flow

  18. Slide 18: Outlook 2026

    Outlook 2026 Key assumptions • Guidance 2026 upgraded on October 8 maintained: • Revenue of DKK ~6,100m (previously DKK Outlook for 2026, upgraded on October 8, maintained ~5,700m) • Travel Health of DKK ~3,400m (previously DKK ~3,000m) • Public Preparedness of DKK ~2,500m • EBITDA margin of ~32% (p

  19. Slide 19: Q&A

    BAVARIAN NORDIC Q&A

  20. Slide 20: Contact details

    Contact details Contact investors: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com Disa Tuominen, IR Manager, detu@bavarian-nordic.com Contact media: Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com

Bavarian Nordic — Q3 2026 Earnings Presentation on 6ix